Volume 31, Issue 2 (Avicenna Journal of Clinical Medicine-Summer 2024)
Avicenna J Clin Med 2024, 31(2): 83-90 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khazaei M, Aminian Z, Mehrpooya M, Khazaei S. Effect of Doxycycline on Clinical Outcomes in Patients with Ischemic Stroke. Avicenna J Clin Med 2024; 31 (2) :83-90
URL: http://sjh.umsha.ac.ir/article-1-3007-en.html
URL: http://sjh.umsha.ac.ir/article-1-3007-en.html
1- Department of Neurology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
3- Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
4- Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran ,salman.khazaei61@gmail.com
2- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
3- Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
4- Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran ,
Abstract: (1132 Views)
Background and Objective: Stroke is the second leading cause of disability and mortality across the globe. The present study aimed to assess the effect of doxycycline on clinical outcomes of patients with ischemic stroke.
Materials and Methods: In this double-blind clinical trial, 60 patients with ischemic stroke were selected in the first 24 hours of post-stroke and randomly assigned to two groups: intervention and control. In the intervention group, patients received 100 mg of doxycycline every 12 hours for seven days in addition to standard treatments. Both groups were followed up before the intervention, on days 7, 30, and 90 after the treatment in terms of the severity of stroke clinical outcomes using National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) tests.
Results: The mean age of patients in the intervention and control groups were 68.33±12.15 and 67.40±9.99 years (P>0.05). No significant difference was observed between the intervention and control groups in terms of NIHSS and mRS scores at baseline and on the seventh day. Nonetheless, in the intervention group, the NIHSS score on days 30 (P=0.007) and 90 (P<0.001), as well as the mRS score on days 30 (P=0.009) and 90 (P<0.01) was significantly less than the control group.
Conclusion: In ischemic stroke, the administration of doxycycline 100 mg every 12 hours for seven days is safe, reduces neurological disorders, and improves the clinical outcome of patients within one to three months after the treatment.
Materials and Methods: In this double-blind clinical trial, 60 patients with ischemic stroke were selected in the first 24 hours of post-stroke and randomly assigned to two groups: intervention and control. In the intervention group, patients received 100 mg of doxycycline every 12 hours for seven days in addition to standard treatments. Both groups were followed up before the intervention, on days 7, 30, and 90 after the treatment in terms of the severity of stroke clinical outcomes using National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) tests.
Results: The mean age of patients in the intervention and control groups were 68.33±12.15 and 67.40±9.99 years (P>0.05). No significant difference was observed between the intervention and control groups in terms of NIHSS and mRS scores at baseline and on the seventh day. Nonetheless, in the intervention group, the NIHSS score on days 30 (P=0.007) and 90 (P<0.001), as well as the mRS score on days 30 (P=0.009) and 90 (P<0.01) was significantly less than the control group.
Conclusion: In ischemic stroke, the administration of doxycycline 100 mg every 12 hours for seven days is safe, reduces neurological disorders, and improves the clinical outcome of patients within one to three months after the treatment.
Extended Abstract [HTML 36 KB] (84 Download)
References
1. Murphy SJ, Werring DJ. Stroke: causes and clinical features. Medicine. 2020;48(9):561-6. PMID: 32837228 DOI: 10.1016/j.mpmed.2020.06.002
2. Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circulation Research. 2017;120(3):439-48. DOI: 10.1161/CIRCRESAHA.116.308413
3. Runchey S, McGee S. Does this patient have a hemorrhagic stroke?: clinical findings distinguishing hemorrhagic stroke from ischemic stroke. Jama. 2010;303(22):2280-6. DOI:10.1001/jama.2010.754
4. Pandya RS, Mao L, Zhou H, Zhou S, Zeng J, Popp AJ, Wang X. Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent Nerv Syst Agents Med Chem. 2011;11(2):81-97. PMID: 21521165 DOI: 10.2174/187152411796011321
5. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011;42(7):1952-5. DOI:10.1161/STROKEAHA.110.612358
6. Weinberg JM. The anti-inflammatory effects of tetr-acyclines. Cutis. 2005;75(4 Suppl):6-11. PMID: 15916224
7. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends in pharmacological sciences. 2004;25(12):609-12. DOI: 10.1016/j.tips.2004.10.001
8. Samartzis EP, Fink D, Stucki M, Imesch P. Doxycycline reduces MMP-2 activity and inhibits invasion of 12Z epithelial endometriotic cells as well as MMP-2 and-9 activity in primary endometriotic stromal cells in vitro. Reprod Biol Endocrinol. 2019;17(1):1-10. DOI: 10.1186/s12958-019-0481-z
9. Smith CJ, Heal C, Vail A, Jeans AR, Westendorp WF, Nederkoorn PJ, et al. Antibiotic class and outcome in post-stroke infections: an individual participant data pooled analysis of VISTA-Acute. Front Neurol. 2019;10:504. DOI: 10.3389/fneur.2019.00504
10. Bostanci N, Akgül B, Tsakanika V, Allaker R, Hughes F, McKay I. Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans. Cytokine. 2011;56(3):656-61. DOI: 10.1016/j.cyto.2011.08.039
11. Clemens DL, Duryee MJ, Sarmiento C, Chiou A, McGowan JD, Hunter CD, et al. Novel antioxidant properties of doxycycline. I Int J Mol Sci. 2018;19(12):4078. DOI: 10.3390/ijms19124078
12. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007;69(14):1404-10. DOI: 10.1212/01.wnl.0000277487.04281.db
13. Cerisano G, Buonamici P, Valenti R, Sciagra R, Raspanti S, Santini A, et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. European heart journal. 2014;35(3):184-91. DOI: 10.1093/eurheartj/eht420
14. Widerøe M, Havnes MB, Morken TS, Skranes J, Goa PE, Brubakk AM. Doxycycline treatment in a neonatal rat model of hypoxia–ischemia reduces cerebral tissue and white matter injury: a longitudinal magnetic resonance imaging study. European Journal of Neuro-science. 2012;36(1):2006-16. DOI: 10.1111/j.1460-9568.2012.08114.x
15. Fathy HA, Soliman AM, Lotfy SM. The Role of Serum Matrix Metalloproteinase-9 as a Prognostic Biomarker for Short-Term Outcome in Acute Ischemic Stroke. Zagazig University Medical Journal. 2023;29(6):1506-14. DOI:10.21608/zumj.2023.222211.2823
16. Modheji M, Olapour S, Khodayar MJ, Jalili A, Yaghooti H. Minocycline is more potent than tetracycline and doxycycline in inhibiting MMP-9 in vitro. Jundishapur Journal Of Natural Pharmaceutical Products. 2016;11(2). [Link]
17. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke. 2002;33(12):2858-64. DOI: 10.1161/01.STR.0000038098.04291.F6
18. Pires PW, Rogers CT, McClain JL, Garver HS, Fink GD, Dorrance AM. Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol . 2011;301(1):H87-97. DOI: 10.1152/ajpheart.01206.2010
19. Clark WM, Lessov N, Lauten JD, Hazel K. Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat. J Mol Neurosci.1997;9:103-8. DOI: 10.1007/BF02736854
20. Reasoner DK, Hindman BJ, Dexter F, Subieta A, Cutkomp J, Smith T. Doxycycline reduces early neurologic impairment after cerebral arterial air embolism in the rabbit. The Journal of the American Society of Anesthesiologists. 1997;87(3):569-76. DOI: 10.1097/00000542-199709000-00017
21. Jiang Y, Zhu J, Wu L, Xu G, Dai J, Liu X. Tetracycline inhibits local inflammation induced by cerebral ischemia via modulating autophagy. PloS one. 2012;7(11):e48672. DOI: 10.1371/journal.pone.0048672
22. Fan X, Lo EH, Wang X. Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats. Stroke. 2013;44(3):745-52. DOI: 10.1161/STROKEAHA.111.000309
23. Seleem M. Benefit of Doxycycline Therapy in Acute St segment Elevation myocardial Infarction with Left Ventricular Dysfunction treated with primary percutaneous coronary intervention (PPCI). American Journal of Research Communication.2015;3(11):55-68. [Link]
24. Wang Q, Wu ZY, Tang HL, Yi ZM, Zhai SD. The efficacy and safety of prophylactic antibiotics for post‐acute stroke infection: A systematic review and meta‐analysis. Br J Clin Pharmacol. 2023;89(3):946-55. DOI:10.1111/bcp.15646
25. Shelat V, Seah M, Lim K. Doxycycline induced acute erosive oesophagitis and presenting as acute dysphagia. J Assoc Physicians India. 2011;59(1):57-9. [Link]
26. Holmes NE, Charles PG. Safety and efficacy review of doxycycline. Clinical Medicine Therapeutics. 2009;1:CMT. S2035. DOI: 10.4137/CMT.S2035
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences
Published by UMSHA Press
Journal Tel: +988138380924
Publisher Tel:+988138380548
Website: http://sjh.umsha.ac.ir
Email: s_ journal[at]umsha.ac.ir
